secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2021-12-16T23:59:59+00:00
Accession:  0001178913-21-003880
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab CEO Dale Pfost expected to become chairman; Stephen Squinto resigns as chairman and director
--------------------------------------------------------------------------------

- Stephen Squinto resigns as chairman and director effective Dec 19, 2021; decision not due to any disagreement with company.
- CEO Dale Pfost, PhD expected to become chairman subject to shareholder vote in or around February 2022.
- Planned succession; Squinto's term was set to lapse by June 2022; transition accelerated to Dec 2021.
- Company advancing Phase 2 programs in primary sclerosing cholangitis, liver fibrosis; Phase 2 trial in systemic sclerosis planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/0001178913-21-003880-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891321003880/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-21-003880

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer